This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rochester Medical's CEO Discusses F2Q11 Results - Earning Call Transcript

Rochester Medical Corp. ( ROCM)

F2Q11 (Qtr End 03/31/11) Earnings Call

May 5, 2011 4:30 pm ET

Executives

Jim Conway - President and CEO

David Jonas - CFO

Analysts

Ernest Andberg - Feltl & Company

Tyson Bauer - Wealth Monitors

Beth Lilly - Gabelli

Presentation

Operator

Good day ladies and gentlemen and welcome to the Q2 2011 Rochester Medical Corp. Earnings Conference Call. My name is Colby and I would be your operator for today. At this time all participants are in listen-only mode. We will conduct a question and answer sessions towards the end of this conference. (Operator's Instructions) As a reminder this call is being recorded for replay purposes.

I would now like to turn the call over to Mr. Anthony J. Conway, President and CEO. Please proceed sir.

Jim Conway

Thank you. Thanks for joining Rochester Medical second quarter conference call. I am Jim Conway, the Company's President and CEO. And with me is David Jonas, Rochester Medical’s Chief Financial Officer.

First I will provide a high level review of our second quarter and speak to our outlook for Rochester Medical and then Dave will provide you with more on our results. Then I will give you a quick summary and then we will take your questions.

Before starting let me remind you that we will be making some forward-looking statements today and I would refer you to the Safe Harbor statement filed in today's press release and also to the risk factors section in the Company's annual report on Form 10 K for the year ended September 30, 2010.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs